前列腺癌SLCO基因表达与Gleason分级及雄激素剥夺治疗后的改变的相关性
本研究系统探索11个人类SLCO基因在未治疗和ADT治疗后的正常前列腺与原发性前列腺癌组织中的表达,包括接受新辅助阿比特龙治疗的肿瘤。结果显示SLCO2B1和SLCO1B3在原发性前列腺癌中可稳定检测到,SLCO1B3在癌与正常组织间差异近5倍,SLCO2B1在Gleason 4与3之间差异近7倍且ADT后升高3倍。作者认为这些发现因样本量小属假设生成性,提示OATP表达变化可能影响类固醇摄取及ADT反应。
要点
- SLCO1B3在原发性前列腺癌中较正常前列腺高近5倍,Gleason 3与4间无差异,ADT后无变化。
- SLCO2B1在原发性前列腺癌中较正常前列腺低3倍,Gleason 4较Gleason 3高近7倍,ADT后升高3倍(p<0.05)。
- 作者认为因样本量小,这些发现属假设生成性,提示OATP表达变化可能影响类固醇摄取及ADT反应。
核心结论
- 在原发性前列腺癌与正常前列腺样本间、Gleason 4与Gleason 3肿瘤间、以及ADT治疗与未治疗组织间观察到SLCO表达的明显差异。
- 作者认为因样本量小,这些发现属假设生成性,但提示基线和ADT诱导的前列腺癌OATP表达变化可能影响类固醇摄取和ADT反应,以及同样受OATP介导转运的阿比特龙和多西他赛等药物的摄取和反应。
研究设计与样本
- 系统探索11个人类SLCO基因在大量未治疗和ADT治疗后的正常前列腺与原发性前列腺癌组织中的表达,包括接受新辅助阿比特龙治疗的肿瘤。
主要发现
- SLCO1B3在原发性前列腺癌中较正常前列腺高近5倍,Gleason 3与4间无差异,ADT后无变化。
- SLCO2B1在原发性前列腺癌中较正常前列腺低3倍,Gleason 4较Gleason 3高近7倍,ADT后升高3倍(p<0.05)。
关键数值与推荐
- SLCO1B3在原发性前列腺癌中较正常前列腺高近5倍,Gleason 3与4间无差异,ADT后无变化。
- SLCO2B1在原发性前列腺癌中较正常前列腺低3倍,Gleason 4较Gleason 3高近7倍,ADT后升高3倍(p<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出因样本量小,这些发现属假设生成性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: SLCO-encoded transporters have been associated with progression to castration-resistant prostate cancer (CRPC) after initiation of androgen deprivation therapy (ADT). Although expressed at lower levels than in CRPC tissues, SLCO-encoded transporters may also play a role in response of primary prostate cancer (PCa) to ADT and biochemical recurrence. METHODS: We systematically explored expression of the 11 human SLCO genes in a large sample of untreated and ADT-treated normal prostate (NP) and primary PCa tissues, including tumors treated with neoadjuvant abiraterone. RESULTS: Transporters with the most recognized role in steroid uptake in PCa, including SLCO2B1 (DHEAS) and 1B3 (testosterone), were consistently detected in primary PCa. SLCO1B3 was nearly 5-fold higher in PCa vs NP with no difference in Gleason 3 vs 4 and no change with ADT. SLCO2B1 was detected at 3-fold lower levels in PCa than NP but was nearly 7-fold higher in Gleason 4 vs Gleason 3 and increased 3-fold following ADT (p < 0.05 for all). CONCLUSIONS: We observed clear differences in SLCO expression in PCa vs NP samples, in Gleason 4 vs Gleason 3 tumors, and in ADT-treated vs untreated tissues. These findings are hypothesis generating due to small sample size, but suggest that baseline and ADT-induced changes in PCa OATP expression may influence steroid uptake and response to ADT, as well as uptake and response to drugs such as abiraterone and docetaxel which are also subject to OATP-mediated transport and are now being routinely combined with ADT in the metastatic castration sensitive setting.
引用
- Alsinnawi M, Zhang A, Bianchi-Frias D, et al. Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy. Prostate Cancer Prostatic Dis. 2019. PMID: 30890759. doi:10.1038/s41391-019-0141-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。